Atomo’s innovative Rapid Diagnostic Test (RDT) platforms simplify procedures, mitigate common user errors and enhance test performance. Atomo products are currently approved for distribution in over 40 countries.
Finished rapid test products are commercialised under Atomo's own brand or under private labels via partners and regional distributors. We hold regulatory approvals including CE Mark in the EU / UK, Australian TGA, and the World Health Organization with near-term opportunities for FDA approval.
HIV 1&2 Test
Atomo offers the world’s first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. Recognised globally for innovative design, performance and ease-of-use. With 99.6% specificity, 99.6% sensitivity, low blood volume and a 24 month shelf life, this test could save 40,000 lives per year in Africa alone.